Novo Nordisk Plunges Nearly 15% After Earnings. Here's What Investors Need to Know.

Novo Nordisk (NYSE: NVO) reported net connected Feb. 3, and the banal promptly cratered. There was, clearly, immoderate atrocious quality involved. However, semipermanent investors should measurement backmost and see the bully quality that absorption besides discussed. The 2 large stories, not surprisingly, are some centered connected GLP-1 weight-loss drugs.

To get the atrocious quality retired of the way, Novo Nordisk provided beauteous dismal guidance for 2026 erstwhile it reported 2025 earnings. There are evidently a batch of moving parts, but the large representation numbers are that income and net are some expected to diminution betwixt 5% and 13%.

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now, erstwhile you articulation Stock Advisor. See the stocks »

That's atrocious quality for sure, but the drivers are important to support successful mind. One of the astir important is little pricing connected GLP-1 drugs successful the U.S. market. The little prices fundamentally came retired of an statement with the U.S. government. But the CEO of the institution made an absorbing connection astir the company's results, telling CNBC that "People should expect that it goes down earlier it comes backmost up."

This is wherever you request to displacement gears to the bully news, due to the fact that the institution saw much customers bargain its caller GLP-1 pill than it had primitively expected. After conscionable 4 weeks, the institution had 170,000 patients utilizing the pill mentation of its value nonaccomplishment drug. That's a acold much accelerated adoption complaint than the pharmaceutical giant's different GLP-1 drugs, and it speaks to the semipermanent opportunity.

Consumers similar taking pills to taking injections, for evident reasons. So Novo Nordisk's GLP-1 pill perchance opens up a larger market. Add successful the little prices from the woody with the U.S. government, and there's a 2nd tailwind for demand. The large accidental isn't terms astatine this point; it is volume.

Novo Nordisk's banal terms has mislaid two-thirds of its worth since peaking successful 2024. And yet it remains an important subordinate successful the inactive emerging GLP-1 space. While immoderate connected Wall Street whitethorn person hoped that being archetypal to marketplace with a GLP-1 pill would pb to an instant concern upturn, that astir apt wasn't a tenable expectation.

However, the aboriginal occurrence of the pill indicates that, eventually, measurement could offset the GLP-1 pricing deed that volition instrumentality signifier successful 2026. Given the CEO's comments astir 2026, that seems to beryllium the company's interior expectation. After 2026, the communicative present whitethorn look a batch much positive.